{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:58:06Z","timestamp":1793656686586,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jdiacomp.2025.109213","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:52:47Z","timestamp":1762282367000},"page":"109213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function"],"prefix":"10.1016","volume":"40","author":[{"given":"Shigehiro","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungGyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Kawanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Ahlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaninder","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109213_bb0005","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Accessed 27 March 2025. https:\/\/diabetesatlas.org\/; 2021."},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0010","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/nep.14051","article-title":"The burden of chronic kidney disease in Asia, 1990\u20132019: examination of estimates from global burden of disease 2019 study","volume":"27","author":"Aashima","year":"2022","journal-title":"Nephrology"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0015","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.672350","article-title":"Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019","volume":"12","author":"Deng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0025","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0030","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/sj.ki.5000326","article-title":"Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL","volume":"69","author":"de Zeeuw","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0040","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.jdiacomp.2025.109213_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nep.13785","article-title":"Asian Pacific Society of Nephrology clinical practice guideline on diabetic kidney disease","volume":"25","author":"Liew","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0050","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0055","series-title":"KERENDIA\u00ae (finerenone) [Summary of Product Characteristics]","year":"2024"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0060","series-title":"KERENDIA\u00ae (finerenone) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0065","author":"Bayer AG"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0070","author":"Bayer India"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0075","series-title":"Kerendia (finerenone) [Kerendia Food and Drug Administration Assessment Report]","year":"2022"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0080","author":"Navlin Daily"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0085","series-title":"Kerendia (finerenone) [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0090","series-title":"Kerendia (finerenone) [Saudi Public Assessment Report (Summary Report) Kerendia]","year":"2022"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0095","series-title":"Kerendia (finerenone) [Health Canada. Product monograph including patient medication information]","year":"2022"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0100","series-title":"Firialta (finerenona) [National Health Surveillance Agency - Anvisa. Firialta\u00ae (finerenona): new registration]","year":"2023"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0105","series-title":"Finerenone [Rep\u00fablica Argentina - Poder Ejecutivo Nacional]","year":"2023"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0110","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0115","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0120","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0125","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ekir.2023.12.010","article-title":"Framework of guidelines for management of CKD in Asia","volume":"9","author":"Pollock","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0130","doi-asserted-by":"crossref","DOI":"10.1159\/000545415","article-title":"Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: a FIDELITY analysis","author":"Wada","year":"2025","journal-title":"Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0145","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1093\/ndt\/gfq189","article-title":"Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients","volume":"25","author":"Barbour","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/dom.14251","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations","volume":"23","author":"Khoo","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0155","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamacardio.2021.5151","article-title":"Potential role and limitations of estimated glomerular filtration rate slope assessment in cardiovascular trials: a review","volume":"7","author":"Khan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0160","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004218","article-title":"Rate and risk factors of kidney function decline among South Asians with type 2 diabetes: analysis of the CARRS trial","volume":"12","author":"Singh","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0170","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0175","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0180","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1210\/clinem\/dgad645","article-title":"Association of urine albumin-to-creatinine ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"109","author":"Zeng","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0190","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ekir.2024.05.025","article-title":"Prospective study on kidney dysfunction markers and risk for mortality among South Asians","volume":"9","author":"Jagannathan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0195","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2369-14-86","article-title":"Ethnic differences in the association between blood pressure components and chronic kidney disease in middle aged and older Asian adults","volume":"14","author":"Sabanayagam","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040214","article-title":"Association between obesity and urinary albumin-creatinine ratio in the middle-aged and elderly population of Southern and Northern China: a cross-sectional study","volume":"11","author":"Qin","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0210","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13300-019-0669-4","article-title":"Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: South Asian Task Force","volume":"10","author":"Kalra","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0215","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries\u2014an expert consensus statement","volume":"28","author":"Liew","year":"2023","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12882-024-03652-5","article-title":"Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes","volume":"25","author":"Khan","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0225","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD prognosis consortium meta-analysis","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0230","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf258","article-title":"Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme","author":"Ferreira","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12882-020-01719-7","article-title":"Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users","volume":"21","author":"Blankenburg","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0240","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0245","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109213_bb0250","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T12:02:05Z","timestamp":1766232125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1056872725002661"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109213","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"109213"}}